GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Price-to-Free-Cash-Flow

MAIA Biotechnology (MAIA Biotechnology) Price-to-Free-Cash-Flow : N/A (As of Jun. 20, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Price-to-Free-Cash-Flow?

As of today (2024-06-20), MAIA Biotechnology's share price is $3.54. MAIA Biotechnology's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.89. Hence, MAIA Biotechnology's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for MAIA Biotechnology's Price-to-Free-Cash-Flow or its related term are showing as below:

MAIA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.09
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

MAIA Biotechnology's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.89.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -78.60% per year.

During the past 4 years, MAIA Biotechnology's highest 3-Year average Free Cash Flow per Share Growth Rate was -78.60% per year. The lowest was -78.60% per year. And the median was -78.60% per year.


MAIA Biotechnology Price-to-Free-Cash-Flow Historical Data

The historical data trend for MAIA Biotechnology's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Price-to-Free-Cash-Flow Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - -

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MAIA Biotechnology's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, MAIA Biotechnology's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MAIA Biotechnology's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's Price-to-Free-Cash-Flow falls into.



MAIA Biotechnology Price-to-Free-Cash-Flow Calculation

MAIA Biotechnology's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.54/-0.892
=N/A

MAIA Biotechnology's Share Price of today is $3.54.
MAIA Biotechnology's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

MAIA Biotechnology  (AMEX:MAIA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


MAIA Biotechnology Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology (MAIA Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606